3,086
Views
32
CrossRef citations to date
0
Altmetric
Research Article

Controlled release of celecoxib inhibits inflammation, bone cysts and osteophyte formation in a preclinical model of osteoarthritis

, , , , , , , , , , , , , & show all
Pages 1438-1447 | Received 02 Apr 2018, Accepted 28 May 2018, Published online: 12 Jun 2018

References

  • Alliston T, Hernandez CJ, Findlay DM, et al. (2017). Bone Marrow Lesions in Osteoarthritis: What Lies Beneath. J Orthopaedic Res. doi: 10.1002/jor.23844 (Epub ahead of print).
  • Andres-Guerrero V, Zong M, Ramsay E, et al. (2015). Novel biodegradable polyesteramide microspheres for controlled drug delivery in ophthalmology. J Control Release 211:105–17.
  • Baker K, Grainger A, Niu J, et al. (2010). Relation of synovitis to knee pain using contrast-enhanced MRIs. Ann Rheum Dis 69:1779–83.
  • Barr AJ, Campbell TM, Hopkinson D, et al. (2015). A systematic review of the relationship between subchondral bone features, pain and structural pathology in peripheral joint osteoarthritis. Arthritis Res Ther 17:228.
  • Botter SM, van Osch GJ, Clockaerts S, et al. (2011). Osteoarthritis induction leads to early and temporal subchondral plate porosity in the tibial plateau of mice: an in vivo microfocal computed tomography study. Arthr Rheumat 63:2690–9.
  • Cross M, Smith E, Hoy D, et al. (2014). The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 73:1323–30.
  • de Boer TN, Huisman AM, Polak AA, et al. (2009). The chondroprotective effect of selective COX-2 inhibition in osteoarthritis: ex vivo evaluation of human cartilage tissue after in vivo treatment. Osteoarthritis Cartilage 17:482–8.
  • de Visser HM, Weinans H, Coeleveld K, et al. (2017). Groove model of tibia-femoral osteoarthritis in the rat. J Orthop Res 35:496–505.
  • Dong J, Jiang D, Wang Z, et al. (2013). Intra-articular delivery of liposomal celecoxib-hyaluronate combination for the treatment of osteoarthritis in rabbit model. Int J Pharm 441:285–90.
  • Dreier R. (2010). Hypertrophic differentiation of chondrocytes in osteoarthritis: the developmental aspect of degenerative joint disorders. Arthritis Res Ther 12:216.
  • Evans CH, Kraus VB, Setton LA. (2014). Progress in intra-articular therapy. Nat Rev Rheumatol 10:11–22.
  • Ferland CE, Laverty S, Beaudry F, Vachon P. (2011). Gait analysis and pain response of two rodent models of osteoarthritis. Pharmacol Biochem Behav 97:603–10.
  • Gerwin N, Bendele AM, Glasson S, Carlson CS. (2010). The OARSI histopathology initiative - recommendations for histological assessments of osteoarthritis in the rat. Osteoarthritis Cartilage 18:S24–S34.
  • Glyn-Jones S, Palmer AJ, Agricola R, et al. (2015). Osteoarthritis. Lancet 386:376–87.
  • Hardisty JF and Eustis SL (1990). Toxicologic pathology: a critical stage in study interpretation. In: Clayson DB, Munro IC, Shubi P, Swenberg JA, eds. Progress in predictive toxicology. New York: Elsevier, 41–62.
  • Holt HL, Katz JN, Reichmann WM, et al. (2011). Forecasting the burden of advanced knee osteoarthritis over a 10-year period in a cohort of 60-64 year-old US adults. OsteoarthritisCartilage 19:44–50.
  • Janssen M, Timur UT, Woike N, et al. (2016). Celecoxib-loaded PEA microspheres as an auto regulatory drug-delivery system after intra-articular injection. J Control Release 244: 30–40.
  • Karsdal MA, Leeming DJ, Dam EB, et al. (2008). "Should subchondral bone turnover be targeted when treating osteoarthritis?". Osteoarthritis Cartilage 16:638–46.
  • Katsarava R, Beridze Z, Arabuli N, et al. (1999). Amino acid-based bioanalogous polymers. Synthesis, and study of regular poly(ester amide)s based on bis(α-amino acid) α, ω-alkylene diesters, and aliphatic dicarboxylic acids. J Polym Sci A Polym Chem 37:391–407.
  • Kon E, Ronga M, Filardo G, et al. (2016). Bone marrow lesions and subchondral bone pathology of the knee. Knee Surg Sports Traumatol Arthrosc 24:1797–814.
  • Lane NE, Brandt K, Hawker G, et al. (2011). OARSI-FDA initiative: defining the disease state of osteoarthritis. Osteoarthritis Cartilage 19:478–82.
  • Larsen C, Ostergaard J, Larsen SW, et al. (2008). Intra-articular depot formulation principles: role in the management of postoperative pain and arthritic disorders. J Pharma Sci 97:4622–54.
  • Li G, Yin J, Gao J, et al. (2013). Subchondral bone in osteoarthritis: insight into risk factors and microstructural changes. Arthritis Res Ther 15:223.
  • Loeser RF, Goldring SR, Scanzello CR, Goldring MB. (2012). Osteoarthritis: a disease of the joint as an organ. Arth Rheumat 64:1697–707.
  • Ma Y, Gao S, Hu M. (2015). Quantitation of celecoxib and four of its metabolites in rat blood by UPLC-MS/MS clarifies their blood distribution patterns and provides more accurate pharmacokinetics profiles. J Chromatogr B, Anal Technol Biomed Life Sci 1001:202–11.
  • Maerz T, Newton MD, Kurdziel MD, et al. (2016). Articular cartilage degeneration following anterior cruciate ligament injury: a comparison of surgical transection and noninvasive rupture as preclinical models of post-traumatic osteoarthritis. Osteoarthritis Cartilage 24:1918–27.
  • Mastbergen SC, Lafeber FP, Bijlsma JW. (2002). Selective COX-2 inhibition prevents proinflammatory cytokine-induced cartilage damage. Rheumatology 41:801–8.
  • McCormack PL. (2011). Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Drugs 71:2457–89.
  • Moskowitz RW, Abramson SB, Berenbaum F, et al. (2007). Coxibs and NSAIDs–is the air any clearer? Perspectives from the OARSI/International COX-2 Study Group Workshop 2007. Osteoarthritis Cartilage 15:849–56.
  • Panahifar A, Jaremko JL, Tessier AG, et al. (2014). Development and reliability of a multi-modality scoring system for evaluation of disease progression in pre-clinical models of osteoarthritis: celecoxib may possess disease-modifying properties. Osteoarthritis Cartilage 22:1639–50.
  • Petit A, Redout EM, van de Lest CH, et al. (2015). Sustained intra-articular release of celecoxib from in situ forming gels made of acetyl-capped PCLA-PEG-PCLA triblock copolymers in horses. Biomaterials 53:426–36.
  • Philp AM, Davis ET, Jones SW. (2017). Developing anti-inflammatory therapeutics for patients with osteoarthritis. Rheumatology 56: 869–81.
  • Pincus T. (2001). Clinical evidence for osteoarthritis as an inflammatory disease. Curr Rheumatol Rep 3:524–34.
  • Pincus T, Koch G, Lei H, et al. (2004). Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis 63:931–9.
  • Roemer FW, Guermazi A, Felson DT, et al. (2011). Presence of MRI-detected joint effusion and synovitis increases the risk of cartilage loss in knees without osteoarthritis at 30-month follow-up: the MOST study. Ann Rheumat Dis 70:1804–9.
  • Rudnik-Jansen I, Colen S, Berard J, et al. (2017). Prolonged inhibition of inflammation in osteoarthritis by triamcinolone acetonide released from a polyester amide microsphere platform. J Control Release 253:64–72.
  • Sawilowsky SS. (2009). New effect size rules of thumb. J Mod App Stat Meth 8:597–9.
  • Sofat N, Ejindu V, Kiely P. (2011). What makes osteoarthritis painful? The evidence for local and central pain processing. Rheumatology 50:2157–65.
  • Solomon DH, Husni ME, Libby PA, et al. (2017). The risk of major NSAID toxicity with celecoxib, ibuprofen, or naproxen: a secondary analysis of the PRECISION trial. Am J Med 130:1415–22.
  • Taljanovic MS, Graham AR, Benjamin JB, et al. (2008). Bone marrow edema pattern in advanced hip osteoarthritis: quantitative assessment with magnetic resonance imaging and correlation with clinical examination, radiographic findings, and histopathology. Skeletal Radiol 37:423–31.
  • Tanamas SK, Wluka AE, Pelletier JP, et al. (2010). The association between subchondral bone cysts and tibial cartilage volume and risk of joint replacement in people with knee osteoarthritis: a longitudinal study. Arthritis Res Ther 12:R58.
  • van Buul GM, Siebelt M, Leijs MJ, et al. (2014). Mesenchymal stem cells reduce pain but not degenerative changes in a mono-iodoacetate rat model of osteoarthritis. J Orthop Res 32:1167–74.
  • van Dalen SC, Blom AB, Sloetjes AW, et al. (2017). Interleukin-1 is not involved in synovial inflammation and cartilage destruction in collagenase-induced osteoarthritis. Osteoarthritis Cartilage 25:385–96.
  • Vargha A, Delaney HD. (2000). A critique and improvement of the CL common language effect size statistics of McGraw and Wong. J Educ Behav Stat 25:101–32.
  • Wang P, Guan PP, Guo C, et al. (2013). "Fluid shear stress-induced osteoarthritis: roles of cyclooxygenase-2 and its metabolic products in inducing the expression of proinflammatory cytokines and matrix metalloproteinases". FASEB J 27:4664–77.
  • Welting TJ, Caron MM, Emans PJ, et al. (2011). Inhibition of cyclooxygenase-2 impacts chondrocyte hypertrophic differentiation during endochondral ossification. eCM 22:420–36.
  • Wolfe F, Zhao S, Lane N. (2000). Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthr Rheumat 43:378–85.
  • Wong SH, Chiu KY, Yan CH. (2016). Review article: osteophytes. J Orthop Surg (Hong Kong) 24:403–10.
  • Yusuf E, Kortekaas MC, Watt I, et al. (2011). Do knee abnormalities visualised on MRI explain knee pain in knee osteoarthritis? A systematic review. Ann Rheum Dis 70:60–7.
  • Zweers MC, de Boer TN, van Roon J, et al. (2011). Celecoxib: considerations regarding its potential disease-modifying properties in osteoarthritis. Arthritis Res Ther 13:239–50.